MORF News and Press, Morphic Holding Inc. From 11/12/19

MORF-720, α v β 6 -targeted oral integrin inhibitor IND now anticipated in the second half of 2020 α 4 β 7 -targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020 Morphic ends third quarter of 2019 with favorable cash, cash equivalents...

WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief exec...

Morphic (NASDAQ: MORF ): Q2 EPS of -$4.73 may not be comparable to consensus of -$0.41. More news on: Morphic Holding, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its two lead programs WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (...

Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...